Commodore Capital XENE Position
Active14-Fund ConvergenceCommodore Capital trimmed their position in Xenon Pharmaceuticals Inc. (XENE) in Q4 2025, holding $80.7M worth of shares across 1,800,000 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
XENE is a convergence signal: 14 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Azetukalner in 137 days (Aug 31, 2026), making the timing of Commodore's position particularly relevant.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Full company profile →Short Interest
6.2%
2.6 days to cover
Commodore Capital XENE Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 1,800,000 | -900,000 | $80.7M |
| Q3 2025 | Decreased | 2,700,000 | -325,000 | $108.4M |
| Q2 2025 | Increased | 3,025,000 | +700,000 | $94.7M |
| Q1 2025 | Decreased | 2,325,000 | -415,000 | $78.0M |
| Q4 2024 | Increased | 2,740,000 | +40,000 | $107.4M |
| Q3 2024 | Decreased | 2,700,000 | -54,266 | $106.3M |
| Q2 2024 | Increased | 2,754,266 | +586,473 | $107.4M |
| Q1 2024 | Held | 2,167,793 | — | $93.3M |
| Q4 2023 | Increased | 2,167,793 | +322,793 | $99.8M |
| Q3 2023 | Held | 1,845,000 | — | $63.0M |
| Q2 2023 | Held | 1,845,000 | — | $71.0M |
| Q1 2023 | New | 1,845,000 | +1,845,000 | $66.0M |
Frequently Asked Questions
Does Commodore Capital own XENE?
Yes. As of Q4 2025, Commodore Capital holds 1,800,000 shares of Xenon Pharmaceuticals Inc. (XENE) valued at $80.7M. This data comes from their SEC 13F filing.
How many hedge funds own XENE?
14 specialist biotech hedge funds currently hold XENE, including Avoro Capital Advisors, Driehaus Capital, BVF Partners and 10 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Commodore Capital first buy XENE?
Commodore Capital's position in XENE was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Commodore Capital's XENE position increasing or decreasing?
Commodore Capital trimmed their XENE position in the most recent quarter, reducing by 900,000 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
XENECompany Page →
All fund holders, insider trades, catalysts, and cash runway
Commodore CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →